CCT measurements a must for all glaucoma patients

Article

Central corneal thickness (CCT) measurements should be carries out on all glaucoma patients in order to help set an accurate target intraocular pressure (IOP) range.

Central corneal thickness (CCT) measurements should be carries out on all glaucoma patients in order to help set an accurate target intraocular pressure (IOP) range, according to Madhu Nagar and colleagues from the Clayton Hospital, West Yorkshire, UK.

A team of researchers carried out a retrospective analysis of existing glaucoma patients at the Clayton and Dewsbury Hospitals, UK between April 2002 and September 2006. IOP was measured using Goldman Tonometry and CCT measured with a hand-held ultrasound pachymeter.

A total of 168 patients were identified for the study. The average CCT was 538.6 µm and corneas were thicker in ocular hypertension patients than in those with normal tension glaucoma. IOP measurements were also found to be higher in patients with thicker corneas. Forty-nine eyes of 35 patients had two CCT readings taken over a period of time but no clinically significant differences were found between the two measurements.

The team suggest that CCT measurements be carried out on all glaucoma patients since the results can help set accurate target IOP ranges, which can in turn help prevent over-treatment.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.